---
type: "Nootropic"
title: "NAC (N-Acetyl Cysteine)"
description: "NAC is involved in cysteine and glutathione metabolism. It has a medical use in acetaminophen poisoning; it is not an equally established general treatment for neuroprotection, OCD or addiction."
resource: "https://nootropikler.com/nootropics/nac"
tags: ["antioxidant", "Glutathione"]
timestamp: 2026-11-11T00:00:00Z
category: "neurotrophic"
source: "semi-synthetic"
latin: "N-Acetylcysteine"
language: "en"
---

# NAC (N-Acetyl Cysteine)

*N-Acetylcysteine*

NAC is involved in cysteine and glutathione metabolism. It has a medical use in acetaminophen poisoning; it is not an equally established general treatment for neuroprotection, OCD or addiction.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | Product- and study-specific |
| Safety | See detailed safety warnings |

> Correction 2026-11-11: Adult and child findings, the OCD trial and cocaine-cue measures were separated. Generic dosing, the unscoped 5.6-hour model and mechanism-based clinical benefits were removed.

## What is NAC?

NAC is involved in cysteine and glutathione metabolism. It has a medical use in acetaminophen poisoning; it is not an equally established general treatment for neuroprotection, OCD or addiction.

## Clinical Trials

Grant 2009: In 50 adults with trichotillomania, NAC 1200–2400 mg/day for 12 weeks reduced hair-pulling symptoms more than placebo. Much/very much improved rates were 56% and 16%.

The accessed abstract does not explicitly report randomization. This small adult trial cannot be generalized to children, all impulse disorders or healthy cognition; its dose is not a personal prescription.

Bloch 2013: In 39 children/adolescents aged 8–17, randomized 12-week add-on NAC did not significantly differ from placebo on primary or secondary hair-pulling outcomes. Response rates were 25% and 21%.

Positive adult findings do not establish pediatric efficacy. Improvement over time in both groups is not a NAC effect; this trial defines neither personal pediatric dosing nor a general safety limit.

Sarris 2022: 98 people with OCD were randomized; 89 with at least one follow-up visit were analyzed. Add-on NAC 2–4 g/day for twenty weeks was not superior to placebo: difference 0.53 (95% interval −2.18–3.23; p=0.70).

Randomized and analyzed populations differ. Doses were adjusted by response; the research range is not a personal titration protocol or replacement for standard psychiatric care.

LaRowe 2007: In 15 cocaine-dependent participants, a double-blind crossover comparison with two three-day hospital stays found less desire/interest and viewing time for cocaine images during NAC.

The abstract does not explicitly verify randomization. Laboratory cue reactivity is not real-world abstinence, relapse prevention or treatment of every addiction.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

The Acepiro oral label reports about two hours plasma half-life after 600 mg and, separately, about six hours mean terminal half-life. Parent compound, metabolites and protein-bound forms are not the same measurement.

No new universal curve replaces the unscoped 5.6 hours. Phase, assay, product and liver status matter; these data do not establish personal redosing or duration of brain effects.

## Safety and Side Effects

The Acepiro label notes that NAC may enhance nitroglycerin vasodilation and requires monitoring for hypotension. The clinical significance of reduced platelet aggregation is unestablished. Breathing difficulty, hypersensitivity and digestive symptoms are among product cautions.

A specific oral drug's cautions do not establish equal side-effect rates for every supplement or proven bleeding increases with every anticoagulant. Do not independently stop medication; missing interaction records do not establish safety.

FDA's August 2022 guidance describes enforcement discretion for certain NAC products meeting specified conditions. This does not mean every NAC product is drug-approved or has identical status in all countries.

The official summary describes policy scope; it is not personal-use permission, a current country/product authorization check or clinical efficacy assessment.


## Frequently Asked Questions

### What does NAC do?

NAC is involved in cysteine and glutathione metabolism. It has a medical use in acetaminophen poisoning; it is not an equally established general treatment for neuroprotection, OCD or addiction.

### How many mg of NAC should be taken per day?

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

### Is NAC better than glutathione supplementation?

NAC supplies cysteine for glutathione synthesis. Oral glutathione has also raised glutathione levels in some controlled human trials; NAC cannot be called superior to every formulation or necessary for everyone.

### What was measured in NAC addiction research?

LaRowe 2007: In 15 cocaine-dependent participants, a double-blind crossover comparison with two three-day hospital stays found less desire/interest and viewing time for cocaine images during NAC. The abstract does not explicitly verify randomization. Laboratory cue reactivity is not real-world abstinence, relapse prevention or treatment of every addiction.

## Sources

- Berk M, et al. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. *Biological Psychiatry*, 64(5), 361–368. [PubMed · PMID 18436195](https://pubmed.ncbi.nlm.nih.gov/18436195/)
- Grant JE, et al. (2009). N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. *Archives of General Psychiatry*, 66(7), 756–763. [PubMed · PMID 19581567](https://pubmed.ncbi.nlm.nih.gov/19581567/)
- LaRowe SD, et al. (2007). Is cocaine desire reduced by N-acetylcysteine? *American Journal of Psychiatry*, 164(7), 1115–1117. [PubMed · PMID 17606664](https://pubmed.ncbi.nlm.nih.gov/17606664/)
- Dean O, et al. (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. *Journal of Psychiatry & Neuroscience*, 36(2), 78–86. [PubMed · PMID 21118657](https://pubmed.ncbi.nlm.nih.gov/21118657/)
- Sarris J, et al. (2022). N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 117, 110550. https://doi.org/10.1016/j.pnpbp.2022.110550 [PubMed · PMID 35304155](https://pubmed.ncbi.nlm.nih.gov/35304155/)
- Richie JP Jr, et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. *European Journal of Nutrition*, 54(2), 251–63. https://doi.org/10.1007/s00394-014-0706-z [PubMed · PMID 24791752](https://pubmed.ncbi.nlm.nih.gov/24791752/)
- US Food and Drug Administration. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine [US Food and Drug Administration](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine)
- Bloch MH, et al. (2013). N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. *Journal of the American Academy of Child and Adolescent Psychiatry*, 52(3), 231-40. https://doi.org/10.1016/j.jaac.2012.12.020 [PubMed · PMID 23452680](https://pubmed.ncbi.nlm.nih.gov/23452680/)
- Stirling Anglian Pharmaceuticals. Acepiro 600 mg effervescent tablets: Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13849/smpc [Stirling Anglian Pharmaceuticals / electronic medicines compendium](https://www.medicines.org.uk/emc/product/13849/smpc)

## Related nootropics

- [curcumin](/okf/nootropics/curcumin.md)
- [Omega-3 DHA/EPA](/okf/nootropics/omega-3.md)
- [Lion's Mane](/okf/nootropics/lions-mane.md)
